Paratek

Paratek was focused on developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and was a VIPE (Venture Investment in Private Equity) for Abingworth. The company was successful in securing regulatory approval for two novel antibiotics. Its lead product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic approved in the US for community-acquired bacterial pneumonia and for acute skin and skin structure infections. Its second approved product, SEYSARA®(sarecycline), is marketed by Almirall, LLC in the U.S. as a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. In September 2023 Novo Holdings and Gurnet Point Capital completed the acquisition of Paratek and took the company private.